Overview
U C B
You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS). The company manufacturers prescription drugs to treat Crohn's disease, epilepsy, and Parkinson's disease. UCB's top products include Cimzia for Crohn's disease,Vimpat to treat epilepsy, and Neupro for Parkinson's disease. The company also makes allergy blockbuster Zyrtec. UCB has operations in nearly 30 countries,
...
Read More and markets its products through an internal sales force and through strategic relationships with other pharmaceutical companies. Marketing, manufacturing, and development partners include AstraZeneca and Novartis. Financière de Tubize owns a majority stake in UCB.
Read Less
Read More and markets its products through an internal sales force and through strategic relationships with other pharmaceutical companies. Marketing, manufacturing, and development partners include AstraZeneca and Novartis. Financière de Tubize owns a majority stake in UCB.
Read Less
Business Support Services
,
Pharmaceutical and Medicine Manufacturing
,
Administrative and Support Services
,
Administrative and Support and Waste Management and Remediation Services
,
Business services, nec
See All Industries , Pharmaceutical preparations Holding companies, nec
See Fewer Industries
See All Industries , Pharmaceutical preparations Holding companies, nec
See Fewer Industries
Employment Services
,
Facilities Support Services
,
Investigation and Security Services
,
Office Administrative Services
,
Other Support Services
,
Remediation and Other Waste Management Services
,
Services to Buildings and Dwellings
,
Travel Arrangement and Reservation Services
View More , Waste Collection Waste Treatment and Disposal
View Less
View More , Waste Collection Waste Treatment and Disposal
View Less
Allée de la Recherche 60 1070, Bruxelles Belgium
See other locations
+32-25599999
188
12,102
$6.26 billion
8.83%
-7.58%
$15,585
1925
1925
Euronext Brussels:UCB
Contacts
Get in Touch with 18 Principals*
A D&B Hoovers Subscription is your foot in the door to U C B contact information.
-
Roch DoliveuxDirector
-
Jonathan PeacockDirector
-
Stefan OschmannDirector
-
Fiona du Monceau de BergendalDirector
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2020 (12 month period) in USD
Annual Revenue
$6.26 billion
USD
1 USD = 0.8546 EUR
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Net Operating Cash | $1,265 | $1,032 | $1,274 |
| Net Investing Cash | -$2,607 | -$275 | -$374 |
| Net Financing Cash | $1,377 | -$708 | -$630 |
| Net Change in Cash | $35 | $49 | $270 |
| Cash at Beginning of Period | $1,507 | $1,447 | $1,196 |
| Cash at End of Period | $1,525 | $1,507 | $1,447 |
| Capital Expenditure | -$408 | -$344 | -$399 |
| Assets (mil) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $1,563 | $1,513 | $1,477 |
| Accounts Receivable | $868 | $803 | $721 |
| Inventories | $999 | $913 | $757 |
| Other Current Assets | $761 | $627 | $497 |
| Asset Summary | |||
| Total Current Assets | $4,191 | $3,856 | $3,452 |
| Tangible Fixed Assets | $1,211 | $983 | $942 |
| Intangible Assets | $3,479 | $982 | $1,018 |
| Total Assets | $15,585 | $12,966 | $12,303 |
| Liabilities (mil) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $600 | $472 | $426 |
| Short-Term Debt | $463 | $314 | $130 |
| Other Current Liabilities | $2,229 | $2,016 | $1,962 |
| Liability Summary | |||
| Total Current Liabilities | $3,293 | $2,801 | $2,518 |
| Long-Term Debt | $2,622 | $1,070 | $1,506 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $7,076 | $4,765 | $4,984 |
| Stakeholder's Equity (mil) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Equity | |||
| Common Stock | $3,059 | $3,059 | $3,059 |
| Retained Earnings | $6,393 | $5,809 | $5,142 |
| Equity Summary | |||
| Total Equity | $8,508 | $8,237 | $7,384 |
| Shares Outstanding | 189,025,436 | 188,583,020 | 188,908,474 |
Before You Go
Don't miss your chance for 50 free email contacts and prospecting data right inside of your inbox.
Don't miss your chance for 50 free email contacts and prospecting data right inside of your inbox.